Trial
NCT02649751
Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Hospital, Brest
Collaborators
ManRos Therapeutics; Cyclacel Pharmaceuticals, Inc.
Condition
Cystic Fibrosis
Intervention
Roscovitine
Why stopped
The centers have no longer patients. In September 2018, set up of a competitive international study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-12